Auvelity can cause dizziness, stomach upset, sleepiness, fatigue, nausea, confusion, increased blood pressure, low sodium, seizures, and other serious reactions. Its boxed warning concerns suicidal thoughts and behaviors, particularly in children and young adults taking antidepressants; Auvelity is not approved for children. Caregivers should nevertheless watch people of every age for sudden changes in mood, behavior, or thinking, especially after treatment begins or the dose changes. For example, if a person becomes newly unsteady and confused after a dose increase, the change should be reported promptly rather than dismissed as dementia progression. Auvelity combines dextromethorphan and bupropion.
It is approved for agitation associated with dementia due to Alzheimer’s disease, but it is not an as-needed rescue medicine and does not treat memory loss or the underlying dementia. Important risks for older adults include falls, medication interactions, hyponatremia, and neuropsychiatric symptoms that may be difficult to distinguish from Alzheimer’s disease itself. The FDA-approved prescribing information calls for blood-pressure monitoring, medication screening, and gradual dose titration based on tolerability. Before the first dose, caregivers should give the prescriber and pharmacist a complete list of prescription drugs, over-the-counter products, supplements, and alcohol use. Cough medicines containing dextromethorphan and depression or smoking-cessation medicines containing bupropion are particularly easy to overlook.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Auvelity Side Effects and Boxed Warning Should Dementia Caregivers Know?
- Common Auvelity Side Effects in Alzheimer’s Agitation
- Understanding Auvelity’s Boxed Warning and Behavioral Changes
- How Caregivers Can Monitor Auvelity Safely
- Serious Risks, Contraindications, and Drug Interactions
- Auvelity Dosing and Administration for Dementia-Related Agitation
- When Auvelity Symptoms Require Prompt or Emergency Help
What Auvelity Side Effects and Boxed Warning Should Dementia Caregivers Know?
In the short-term study involving people with agitation associated with Alzheimer’s dementia, the most common auvelity side effects meeting the label’s threshold were dizziness and dyspepsia, a category that includes stomach discomfort, indigestion, upper abdominal pain, gastritis, and reflux. Dizziness occurred in 9% of Auvelity-treated participants and 3% of those receiving placebo; dyspepsia occurred in 6% and 1%, respectively. Sleepiness, fatigue, nausea or vomiting, dry mouth, headache, constipation, psychotic symptoms, and confusional states were also reported more often with Auvelity than with placebo. Those numbers describe groups in a controlled trial, not what will happen to a particular person.
A side effect affecting balance may be far more consequential for someone who already uses a walker than for someone with a steady gait. Similarly, mild indigestion may be manageable, while reduced eating and drinking can contribute to dehydration, weakness, or medication problems in a frail adult. The boxed warning is not a prediction that an older person will become suicidal. It reflects evidence from antidepressant studies showing increased suicidal thoughts and behaviors in pediatric and young adult patients. Still, the label directs caregivers to monitor every antidepressant-treated patient for clinical worsening or emerging suicidal thoughts and behavior, especially during the first months of treatment and around dose changes.
Common Auvelity Side Effects in Alzheimer’s Agitation
Dizziness deserves special attention because it can lead directly to a fall. A caregiver may first notice that the person reaches for furniture, hesitates before standing, or veers when walking to the bathroom. Sleepiness and fatigue can add to that risk, particularly when Auvelity is taken with other medicines that cause sedation. Until its effects are known, driving and hazardous activities should be avoided. Digestive effects can appear as belching, complaints of stomach pain, refusal of meals, nausea, vomiting, or constipation.
People with limited speech may instead guard their abdomen, grimace during meals, or become more agitated. Recording when the symptom occurs in relation to each dose can help the prescriber distinguish a medication effect from infection, constipation, reflux, or another medical problem. The main safety limitation is that the placebo-controlled adverse-effect data for Alzheimer’s agitation came from a five-week study. Trial participants had probable Alzheimer’s disease, moderate-to-severe agitation requiring medication, and defined ranges of cognitive impairment. Short-term percentages cannot establish the frequency of uncommon reactions during long-term treatment or predict tolerability in someone with substantially different health problems. The current DailyMed label specifically cautions that clinical-trial rates may not reflect routine practice.
Understanding Auvelity’s Boxed Warning and Behavioral Changes
The boxed warning focuses on suicidal thoughts and behaviors in younger patients, but caregivers of older adults should still report new hopelessness, statements about wanting to die, self-harm behavior, dangerous impulsivity, severe restlessness, aggression, or abrupt mood changes. Dementia can make direct questioning difficult, so behavior may carry more information than a verbal denial. Giving away valued belongings, trying to leave home in a dangerous situation, or refusing essential care while expressing a wish to die warrants prompt clinical assessment. Auvelity can also activate mania or hypomania, particularly in people with bipolar disorder or related risk factors.
Warning signs include dramatically reduced need for sleep, racing thoughts, unusually fast speech, excessive energy, grand ideas, reckless behavior, or marked irritability. The prescriber should know about any personal or family history of bipolar disorder, mania, hypomania, depression, or suicide before treatment begins. Bupropion, one of Auvelity’s ingredients, has also been associated with hallucinations, delusions, paranoia, psychosis, concentration problems, and confusion. These symptoms overlap with dementia, delirium, and the agitation being treated. If a person who occasionally misidentifies family members suddenly sees frightening figures, becomes intensely paranoid, or is much more disoriented after titration, the timing should be reported instead of assuming the Alzheimer’s disease has rapidly worsened.
How Caregivers Can Monitor Auvelity Safely
Before treatment, ask the clinical team to review blood pressure, fall history, gait problems, seizure risks, kidney and liver function, bipolar history, glaucoma risk, alcohol use, and every medication the person takes. Older adults using diuretics or those prone to dehydration have a greater risk of low sodium. A clinician may decide that symptoms or risk factors justify laboratory monitoring, but caregivers should not change medicines or fluid intake without guidance. Keep a simple daily record of doses, agitation, sleep, alertness, appetite, stomach symptoms, confusion, balance, falls, and blood-pressure readings if home monitoring has been recommended.
Use observable descriptions rather than labels: “needed help standing twice after the morning dose” is more useful than “seemed off.” Comparing the same behaviors before and after treatment helps separate a possible benefit from sedation that merely makes the person quieter. There is a tradeoff between controlling dangerous agitation and preserving alertness, mobility, and participation. A reduction in hitting or pacing may be meaningful, but spending most of the day asleep or becoming unable to walk safely is not automatically an acceptable response. The prescriber may need to reconsider the dose, titration pace, interacting drugs, or treatment choice; caregivers should not make those changes independently.
Serious Risks, Contraindications, and Drug Interactions
Auvelity can cause seizures, and the risk is dose-related. It must not be used in people with a seizure disorder, a current or past diagnosis of anorexia nervosa or bulimia, or abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiseizure medicines. Severe head injury, severe stroke, low sodium, low blood sugar, hypoxia, and medicines that lower the seizure threshold can add risk. If a seizure occurs, the label says to stop Auvelity and not restart it; emergency evaluation may also be necessary. Dextromethorphan can contribute to serotonin syndrome when combined with serotonergic medicines, including some antidepressants.
Possible signs include agitation, confusion, sweating, fever, rapid heartbeat, tremor, muscle rigidity or twitching, poor coordination, blood-pressure changes, vomiting, and diarrhea. Monoamine oxidase inhibitors are contraindicated with Auvelity, including within the required separation period; linezolid and intravenous methylene blue also require special attention because they have MAOI activity. Medication reconciliation must include nonprescription products. A cough-and-cold medicine may contain dextromethorphan, while bupropion may appear in treatment for depression or smoking cessation. Other important interactions involve strong CYP2D6 inhibitors, drugs metabolized through CYP2D6, digoxin, levodopa, amantadine, nicotine replacement, and medicines that lower the seizure threshold. Auvelity can also produce a false-positive urine screening result for amphetamines, so the testing clinician should know the person is taking bupropion.
Auvelity Dosing and Administration for Dementia-Related Agitation
For agitation associated with Alzheimer’s dementia, the labeled schedule begins with the 30 mg/105 mg tablet once each morning. Based on tolerability, it increases on day 8 to that strength twice daily and on day 15 to 45 mg/105 mg twice daily, with doses at least eight hours apart. Kidney impairment, certain interacting medicines, or a known CYP2D6 poor-metabolizer status may require a different schedule.
Auvelity is not intended for occasional use during an agitation episode. The extended-release tablet must be swallowed whole, not crushed, divided, or chewed, and it may be taken with or without food. If a dose is missed, the FDA Medication Guide says not to take an extra dose; the person should wait until the next scheduled dose. For example, a forgotten morning tablet should not be doubled with the later dose.
When Auvelity Symptoms Require Prompt or Emergency Help
Seek emergency help for a seizure, suicide attempt, imminent self-harm, collapse, severe breathing difficulty, or a combination suggesting serotonin syndrome, such as fever with agitation, confusion, sweating, tremor, and rigid or twitching muscles. Rash, hives, facial swelling, shortness of breath, chest pain, or fever can indicate an allergic reaction. Sudden eye pain, visual changes, or redness and swelling around the eye may signal angle-closure glaucoma.
Contact the prescriber promptly about new hallucinations, paranoia, mania-like behavior, marked sleepiness, falls, rising blood pressure, persistent vomiting, or worsening agitation. Headache, weakness, memory changes, increased confusion, and unsteadiness may indicate hyponatremia rather than ordinary dementia fluctuation; severe low sodium can lead to fainting, seizures, coma, respiratory arrest, or death. Auvelity should remain in its original bottle at 68°F to 77°F and out of children’s reach.
